Computed Tomography trials for Prostate cancer

All Computed Tomography trials · All Prostate cancer trials

Phase breakdown

Recruiting trials studying Computed Tomography for Prostate cancer

• 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
  NCT07219147 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
  NCT04857502 · Phase: Early Phase 1 · Ages: No age limits stated · Sex: Male · 1 location
• Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
  NCT06389786 · Phase: Not applicable (e.g. observational or device study) · Ages: 30 Years to 85 Years · Sex: Male · 1 location
• Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer
  NCT06325046 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 5 locations
• An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
  NCT07185165 · Phase: Phase 2 · Ages: 18 Years to 90 Years · Sex: Male · 1 location
• An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
  NCT06813898 · Phase: Early Phase 1 · Ages: No age limits stated · Sex: Male · 1 location
• Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
  NCT07025369 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
  NCT05806515 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 133 locations
• Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT06236139 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
  NCT07164027 · Phase: Early Phase 1 · Ages: 18 Years to 90 Years · Sex: Male · 1 location
• FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
  NCT06244004 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 6 locations
• Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
  NCT06067269 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial
  NCT07276438 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location
• Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
  NCT06526299 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
  NCT07698535 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
  NCT07202247 · Phase: Phase 2 · Ages: 30 Years to 79 Years · Sex: Male · 1 location
• PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
  NCT05805371 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
  NCT06216249 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
  NCT04175431 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
  NCT06288113 · Phase: Phase 2 · Ages: No age limits stated · Sex: Male · 1 location
• Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
  NCT06499870 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
  NCT06369610 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
  NCT06616155 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
  NCT06378866 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
  NCT06039371 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
  NCT06632977 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 108 locations
• Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
  NCT07200830 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 129 locations
• Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
  NCT05946213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 413 locations
• Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
  NCT06470243 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 174 locations
• Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
  NCT06931340 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 210 locations
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
  NCT03866382 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 581 locations
• Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
  NCT05691465 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 13 locations
• Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
  NCT04423211 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 341 locations
• Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
  NCT06145633 · Phase: Phase 2 · Ages: No age limits stated · Sex: Male · 1 location

Common questions

How many trials study Computed Tomography for Prostate cancer?

34 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.